Practice guideline for the greatment of patients with Alzheimer's disease and other dementias of late life

American Journal of Psychiatry

Volumn 154, Issue 5 SUPPL., 1997, Pages 1-39

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIHYDROERGOTOXINE MESILATE; DIPHENHYDRAMINE; DONEPEZIL; IMIPRAMINE; LITHIUM; MEDROXYPROGESTERONE ACETATE; MONOAMINE OXIDASE INHIBITOR; RISPERIDONE; SELEGILINE; TACRINE; TRAZODONE; TRIAZOLAM; VALPROIC ACID; VENLAFAXINE;

AGRANULOCYTOSIS; ALZHEIMER DISEASE; CLINICAL PROTOCOL; COGNITIVE DEFECT; DEPRESSION; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; MULTIINFARCT DEMENTIA; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; TREATMENT PLANNING;

EID: 0030898844     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.5.1     Document Type: Review

References (243)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington, DC, APA, 1994 [G]
2. Alexopoulos G, Meyers BS, Young RC, Mattis S, Kakuma T: The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry 1993; 150:1693-1699 [C]
3. Shergill S, Mullan E, D'Ath P, Katona C: What is the clinical prevalence of Lewy body dementia? Int J Geriatr Psychiatry 1994; 9:907-912 [G]
4. Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139:1136-1139 [G]
5. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572 [G]
6. Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, Funkenstein HH, Evans DA: Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995; 273:1354-1359 [C]
7. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997; 277:813-817 [C]
8. Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Sano M, Hauser WA, Mayeux R: Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994; 44:1885-1891 [C]
9. McKeith IG, Fairbairn AF, Perry RH, Thompson P: The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994; 165:324-332 [G]
10. Rabins P, Nicholson M: Acute psychiatric hospitalization for patients with irreversible dementia. Int J Geriatr Psychiatry 1991; 6:209-211 [G]
11. Zubenko GS, Rosen J, Sweet RA, Mulsant BH, Rifai AH: Impact of psychiatric hospitalization on behavioral complications of Alzheimer's disease. Am J Psychiatry 1992; 149:1484-1491 [B]
12. NIH Consensus Development Panel on the Differential Diagnosis of Dementing Diseases: Differential diagnosis of dementing diseases. JAMA 1987; 258:3411-3416 [G]
13. Okagaki JF, Alter M, Byrne TN, Daube JR, Franklin G, Frishberg BM, Goldstein ML, Greenberg MK, Lanska DJ, Mishra S, Odenheimer GL, Paulson G, Pearl RA, Rosenberg JH, Sila C, Stevens JC: Practice parameter for diagnosis and evaluation of dementia. Neurology 1994; 44:2203-2206 [G]
14. Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias: Clinical Practice Guideline, vol 19. Washington, DC, US Department of Health and Human Services, Agency for Health Care Policy and Research, 1996 [G]
15. American Psychiatric Association: Practice Guideline for Psychiatric Evaluation of Adults. Am J Psychiatry 1995; 152(Nov suppl):63-80 [G]
16. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198 [G]
17. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer's Disease: Statement on use of apolipoprotein E testing for Alzheimer's disease. JAMA 1995; 274:1627-1629 [G]
18. National Institute on Aging/Alzheimer's Association Working Group: Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996; 347:1091-1095 [G]
19. Hussian RA, Brown DC: Use of two-dimensional grid patterns to limit hazardous ambulation in demented patients. J Gerontol 1987; 42:558-560 [B]
20. Namazi KH, Rosner TT, Calkins MP: Visual barriers to prevent ambulatory Alzheimer's patients from exiting through an emergency door. Gerontologist 1989; 29:699-702 [B]
21. Mayer R, Darby SJ: Does a mirror deter wandering in demented older people? Int J Geriatr Psychiatry 1991; 6:607-609 [B]
22. Hunt L, Morris JC, Edwards D, Wilson BA: Driving performance in persons with mild senile dementia of the Alzheimer type. J Am Geriatr Soc 1993; 41:747-753 [B]
23. Friedland RP, Koss E, Kumar A, Gaine S, Metzler D, Haxby J, Moore A: Motor vehicle crashes in dementia of the Alzheimer type. Ann Neurol 1988; 24:782-786 [C]
24. Dubinsky RM, Williamson A, Gray CS, Glatt SL: Driving in Alzheimer's disease. J Am Geriatr Soc 1992; 40:1112-1116 [G]
25. Drachman DA, Swearer JM: Driving and Alzheimer's disease: the risk of crashes. Neurology 1993; 43:2448-2456 [D]
26. Fitten LJ, Perryman KM, Wilkinson CJ, Little RJ, Burns MM, Pachana N, Mervis JR, Malmgren R, Siembieda DW, Ganzell S: Alzheimer and vascular dementias and driving: a prospective road and laboratory study. JAMA 1995; 273:1360-1365 [C]
27. Tuokko H, Tallman K, Beatti BL, Cooper P, Weir J: An examination of driving records in a dementia clinic. J Gerontol 1995; 50:5173-5181 [G]
28. Trobe JD, Waller PF, Cook-Flannagan CA, Teshima SM, Bieliauskas LA: Crashes and violations among drivers with Alzheimer disease. Arch Neurol 1996; 53:411-416 [D]
29. Lucas-Blaustein MJ, Filipp L, Dungan C, Tune L: Driving in patients with dementia. J Am Geriatr Soc 1988; 36:1087-1091 [G]
30. Gilley DW, Wilson RS, Bennett DA, Stebbins GT, Bernard BA, Whalen ME, Fox JH: Cessation of driving and unsafe motor vehicle operation by dementia patients. Arch Intern Med 1991; 151:941-946 [G]
31. Carr D, Jackson T, Alquire P: Characteristics of an elderly driving population referred to a geriatric assessment center. J Am Geriatr Soc 1990; 38:1145-1150 [D]
32. O'Neill D, Neubauer K, Boyle M, Gerrard J, Surmon D, Wilcock GK: Dementia and driving. J R Soc Med 1992; 85:199-202 [G]
33. Odenheimer GL, Beaudet M, Jette AM, Albert MS, Grande L, Minaker KL: Performance-based driving evaluation of the elderly driver: safety, reliability, and validity. J Gerontol 1994; 49(4): M153-M159 [G]
34. Adler G, Rottunda SJ, Dysken MW: The driver with dementia: a review ot the literature. Am J Geriatr Psychiatry 1996; 4:110-120 [F]
35. Shua-Haim JR, Gross JS: The co-pilot driver syndrome. J Am Geriatr Soc 1996; 44:815-817 [G]
36. Drickamer MA, Lachs MS: Should patients with Alzheimer's disease be told their diagnosis? N Engl J Med 1992; 326:947-951 [G]
37. Stern Y, Tang M-X, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai W-Y: Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277:806-812 [C]
38. Mace NL, Rabins PV: The Thirty-Six Hour Day: A Family Guide to Caring for Persons With Alzheimer's Disease, Related Dementing Illness, and Memory Loss in Later Life, 2nd revised ed. New York, Warner Books, 1992 [G]
39. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704-706 [G]
40. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J-F, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Po D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HAR, Hai JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, George-Hyslop PH: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375:754-760 [G]
41. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, Crowley AC, Fu YH, Guenette SY, Galas D, Nemens E, Wijsman EM, Bird TD, Schellenberg GD, Tanzi RE: Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269:973-977 [G]
42. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90:1977-1981 [G]
43. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ: Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43:1467-1472 [G]
44. Locke PA, Conneally PM, Tanzi RE, Gusella JF, Haines JL: Apolipoprotein E4 allele and Alzheimer disease: examination of allelic association and effect on age at onset in both early- and late-onset cases. Genet Epidemiol 1995; 12:83-92 [G]
45. Chiverton P, Caine ED: Education to assist spouses in coping with Alzheimer's disease. J Am Geriatr Soc 1989; 37:593-598 [C]
46. Mittelman MS, Ferris SH, Steinberg G, Shulman E, Mackell JA, Ambinder A, Cohen J: An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. Gerontologist 1993; 33:730-740 [A]
47. Brodaty H, Peters KE: Cost effectiveness of a training program for dementia carers. Int Psychogeriatr 1991; 3:11-22 [G]
48. Lovett S, Gallagher D: Psychoeducational interventions for family caregivers: preliminary efficacy data. Behav Ther 1988; 19: 321-330 [B]
49. Gallagher-Thompson D: Direct services and interventions for caregivers: a review and critique of extant programs and a look ahead to the future, in Family Caregiving: Agenda for the Future. Edited by Cantor MM. San Francisco, American Society on Aging, 1994, pp 102-122 [G]
50. Flint AJ: Effects of respite care on patients with dementia and their caregivers. Int J Psychogeriatr 1995; 7:505-517 [F]
51. Burdz M, Eaton W, Bond J: Effect of respite care on dementia and nondementia patients and their caregivers. Psychol Aging 1988; 3:38-42 [G]
52. Conlin MM, Caranasos GJ, Davidson RA: Reduction of caregiver stress by respite care: a pilot study. South Med J 1992; 85:1096-1100 [B]
53. Wimo A, Mattsson B, Adolfsson R, Eriksson T, Nelvig A: Dementia day care and its effects on symptoms and institutionalization - a controlled Swedish study. Scand J Prim Health Care 1993; 11:117-123 [B]
54. Overman W Jr, Stoudemire A: Guidelines for legal and financial counseling of Alzheimer's disease patients and their families. Am J Psychiatry 1988; 145:1495-1500 [G]
55. Spar JE, Garb AS: Assessing competency to make a will. Am J Psychiatry 1992; 149:169-174 [G]
56. Robinson A, Spencer W, White L: Understanding Difficult Behaviors. Lansing, Mich, Geriatric Education Center of Michigan, 1988 [G]
57. Mintzer JE, Lewis L, Pennypacker L, Simpson W, Bachman D, Wohlreich G, Meeks A, Hunt S, Sampson R: Behavioral intensive care unit (BICU): a new concept in the management of acute agitated behavior in elderly demented patients. Gerontologist 1993; 33:801-806 [G]
58. Burgio LD, Engel BT, Hawkins AM, McCormick KA, Scheve A, Jones LT: A staff management system for maintaining improvements in continence with elderly nursing home residents. J Appl Behav Anal 1990; 23:111-118 [G]
59. Group for the Advancement of Psychiatry Committee on Aging: The Psychiatric Treatment of Alzheimer's Disease: Report 125. New York, Brunner/Mazel, 1988 [G]
60. Burnside I, Haight B: Reminiscence and life review: therapeutic interventions for older people. Nurse Pract 1994; 19(4):55-61 [F]
61. Jones GM: Validation therapy: a companion to reality orientation. Can Nurse 1985; 81(3):20-23 [G]
62. Feil N: The Feil Method - How to Help Disoriented Old-Old. Cleveland, Edward Feil Productions, 1992 [G]
63. Robichaud L, Hebert R, Desrosiers J: Efficacy of a sensory integration program on behaviors of inpatients with dementia. Am J Occup Ther 1994; 48:355-360 [A]
64. Woods P, Ashley J: Simulated presence therapy: using selected memories to manage problem behaviors in Alzheimer's disease patients. Geriatr Nurs 1995; 16(1):9-14 [B]
65. Baines S, Saxby P, Ehlert K: Reality orientation and reminiscence therapy: a controlled cross-over study of elderly confused people. Br J Psychiatry 1987; 151:222-231 [A]
66. Kiernat JM: The use of life review activity with confused nursing home residents. Am J Occup Ther 1979; 33:306-310 [B]
67. Cook J: Reminiscing: how can it help confused nursing home residents? Social Casework 1984; 65:90-93 [G]
68. Scanland SG, Emershaw LE: Reality orientation and validation therapy: dementia, depression, and functional status. J Gerontol Nurs 1993; 19:7-11 [B]
69. Powell-Proctor L, Miller E: Reality orientation: a critical appraisal. Br J Psychiatry 1982; 140:457-463 [F]
70. Tappen RM: The effect of skill training on functional abilities of nursing home residents with dementia. Res Nurs Health 1994; 17:159-165 [B]
71. Hanley IG, McGuire RJ, Boyd WD: Reality orientation and dementia: a controlled trial of two approaches. Br J Psychiatry 1981; 138:10-14 [A]
72. Koh K, Ray R, Lee J, Nair A, Ho T, Ang P: Dementia in elderly patients: can the 3R mental stimulation programme improve mental status? Age Aging 1994; 23:195-199 [B]
73. Johnson CH, McLaren SM, McPherson FM: The comparative effectiveness of three versions of "classroom" reality orientation. Age Aging 1981; 10:33-35 [B]
74. Woods RT: Reality orientation and staff attention: a controlled study. Br J Psychiatry 1979; 134:502-507 [A]
75. Brook P, Degun G, Mather M: Reality orientation, a therapy for psychogeriatric patients: a controlled study. Br J Psychiatry 1975; 127-A2-45 [B]
76. Greene JG, Timbury GC, Smith R: Reality orientation with elderly patients in the community: an empirical evaluation. Age Ageing 1983; 12:38-43 [B]
77. Reeve W, Ivison D: Use of environmental manipulation and classroom and modified informal reality orientation with institutionalized, confused elderly patients. Age Ageing 1985; 14-119-121 [B]
78. Williams R, Reeve W, Ivison D, Kavanagh D: Use of environmental manipulation and modified informal reality orientation with institutionalized, confused, elderly subjects: a replication. Age Ageing 1987; 16:315-318 [B]
79. Gerber GJ, Prince PN, Snider HG, Atchinson K, Dubois L, Kilgour JA: Group activity and cognitive improvement among patients with Alzheimer's disease. Hosp Community Psychiatry 1991; 42:843-845 [A]
80. Baldelli MV, Pirani A, Motta M, Abati E, Mariani E, Manzi V: Effects of reality orientation therapy on elderly patients in the community. Arch Gerontol Geriatr 1993; 7:211-218 [B]
81. Dietch JT, Hewett LJ, Jones S: Adverse effects of reality orientation. J Am Geriatr Soc 1989; 37:974-976 [B]
82. Beck C, Heacock P, Mercer S, Thatcher R, Sparkman C: The impact of cognitive skills remediation training on persons with Alzheimer's disease or mixed dementia. J Geriatr Psychiatry 1988; 21:73-88 [A]
83. Zarit SH, Zarit JM, Reever KE: Memory training for severe memory loss: effects on senile dementia patients and their families. Gerontologist 1982; 22:373-377 [A]
84. Yesavage JA, Westphal J, Rush L: Senile dementia: combined pharmacologic and psychologic treatment. J Am Geriatr Soc 1981; 29:164-171 [A]
85. McEvoy CL, Patterson RL: Behavioral treatment of deficit skills in dementia patients. Gerontologist 1986; 26:475-478 [B]
86. Abraham IL, Reel SJ: Cognitive nursing interventions with long-term care residents: effects on neurocognitive dimensions. Arch Psychiatr Nurs 1992; 6:356-365 [B]
87. Karlsson I, Brane G, Melin E, Nyth AI, Rybo E: Effects of environmental stimulation on biochemical and psychological variables in dementia. Acta Psychiatr Scand 1988; 77:207-213 [B]
88. Rovner BW, Steel CD, Shmuely Y, Folstein MF: A randomized trial of dementia care in nursing homes. J Am Geriatr Soc 1996; 44:7-13 [B]
89. Teri L: Behavioral treatment of depression in patients with dementia. Alzheimer Dis Assoc Disord 1994; 8(3):66-74 [B]
90. Teri L, Logsdon RG: Identifying pleasant activities for Alzheimer's disease patients: the Pleasant Events Schedule-AD. Gerontologist 1991; 31:124-127 [G]
91. Sunderland T, Weingartner H, Cohen RM, Tariot PN, Newhouse PA, Thompson KE, Lawlor BA, Mueller EA: Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology (Berl) 1989; 99:129-133 [D]
92. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS, Tacrine Collaborative Study Group: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259 [A]
93. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J: A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529 [A]
94. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991 [A]
95. Forette F, Hoover T, Gracon S, de Rotrou J, Hervy MP: A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease. Eur J Neurology 1995; 2:1-10 [A]
96. Foster NL, Petersen RC, Gracon SI, Lewis K, Tacrine 970-6 Study Group: An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. Dementia 1996; 7:260-266 [A]
97. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S: Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47:166-177 [C]
98. Rogers SL, Doody R, Mohs R, Friedhoff LT: E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: results of a 30-week phase III trial (abstract). Neurology 1996; 46:A217 [A]
99. Rogers SL, Friedhoff LT, Apter JT, Richter RW, Hartford JT, Walshe TM, Baumel B, Linden RD, Kinney FC, Doody RS, Borison RL, Ahem GL: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7:293-303 [A]
100. Rogers SL, Friedhoff LT: Donepezil (E2020) produces long-term clinical improvement in Alzheimer's disease. Presented at the 4th International Nice/Springfield Symposium on Advances in Alzheimer Therapy, April 10-14, 1996 [A]
101. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271:992-998 [C]
102. Lyketsos CG, Corazzini K, Steele CD, Kraus MF: Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. J Neuropsychiatry Clin Neurosci 1996; 8:67-73 [F]
103. Halliwell B, Gutteridge JMC: Oxygen radicals in the nervous system. Trends Neurosci 1985; 8:22-26 [G]
104. Behl C, Davis J, Cole G, Shubert D: Vitamin E protects nerve cells from beta-amyloid protein toxicity. Biochem Biophys Res Commun 1992; 186:944-950 [G]
105. Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman F, Growdon S, Thal LJ: Rationale and design of a multicenter study of selegiline and α-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Dis Assoc Disord 1996; 10:132-140 [G]
106. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ: A two-year, double blind randomized multicenter trial of selegeline and α-tocopherol in the treatment of Alzheimer's disease. N Engl J Med (in press) [A]
107. Kappus H, Diplock AT: Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med 1992; 13:55-74 [G]
108. Tatton WG, Greenwood CE: Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991; 30:666-672 [G]
109. Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S: Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 1991; 31:100-107; correction 31:433 [A]
110. Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK: L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41:1219-1225 [A]
111. Burke WJ, Ranno AE, Roccaforte WH, Wengel SP, Bayer BL, Willcockson NK: L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. J Am Geriatr Soc 1993; 41:367-370 [A]
112. Agnoli A, Martucci N, Fabbrini G, Buckley AE, Fioravanti M: Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1990; 1:109-114 [A]
113. Filip V, Kolibas E, Ceskova E, Hronek J, Novotna D, Novotny V: Selegiline in mild SDAT: results of a multi-center, double-blind, placebo-controlled trial (abstract). Neuropsychopharmacol 1991[A]
114. Loeb C, Albano C: Selegiline: a new approach to DAT treatment (abstract). Presented at the European Conference on Parkinson's Disease and Extrapyramidal Disorders, Rome, July 1990 [A]
115. Martucci N, Fabbrini G, Fioravanti M: Monoaminossidasi e demenza: trattamento con un inibitore dell'attivita MAO-B. Giornale di Neuropsicofarmacologia 1989; 11:265-269 [A]
116. Schneider LS, Olin JT: Overview of clinical trials of Hydergine in dementia. Arch Neurol 1994; 51:787-798 [E]
117. Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA, Murphy DL: L-deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44:427-433 [A]
118. Piccinin GL, Finali G, Piccirilli M: Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 1990; 13:147-163 [A]
119. Finali G, Piccirilli M, Oliani C, Piccinin GL: L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol 1991; 14:523-536 [B]
120. Schneider LS, Olin JT, Pawluczyk S: A double-blind crossover pilot study of 1-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Am J Psychiatry 1993; 150:321-323 [A]
121. Thompson TL II, Filley CM, Mitchell WD, Culig KM, LoVerde M Byyny RL: Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med 1990; 323:445-448; correction 323:691 [A]
122. McDonald WM, Krishnan KR: Pharmacologic management of the symptoms of dementia. Am Fam Physician 1990; 42:123-132 [A]
123. Irfan S, Linder L: The effect of dihydrogenated ergot alkaloids in the treatment of geriatric patients suffering from senile mental deterioration, in XIth International Congress of Gerontology. Tokyo, SCIMED, 1978, p 142 [A]
124. Puxty J: Community screening for dementia and evaluation of treatment, in Proceedings of the Basel Symposium (CH). Edited by Carlsson A, Kanowski S, Allain H, Spiegel R. Pearl River, NY, Parthenon Publishing Group, 1989, p 211-230 [A]
125. Soni SD, Soni SS: Dihydrogenated alkaloids of ergotoxine in nonhospitalised elderly patients. Curr Med Res Opin 1975; 3: 464-468 [A]
126. Thienhaus OJ, Wheeler BG, Simon S, Zemlan FP, Hartford JT: A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia. J Am Geriatr Soc 1987; 35:219-223 [A]
127. Rao DB, Norris JR: A double-blind investigation of hydergine in the treatment of cerebrovascular insufficiency in the elderly. Johns Hopkins Med J 1972; 130:317-324 [B]
128. Winslow IE: Clinical evaluation of hydergine. Unpublished manuscript, 1972 [A]
129. Lazzari R, Passeri M, Chierichetti SM: Le mésylate de dihydroergotoxine dans le traitement de l'insuffisance cérébrale sénile. Le Presse Médicale 1983; 12:3179-3185 [A]
130. Martucci N, Manna V: EEG-pharmacological and neuropsychological study of dihydroergocristine mesylate in patients with chronic cerebrovascular disease. Advances in Therapy 1986; 3:210-223 [A]
131. Moglia A, Bono G, Sinforiani E, Alfonsi E, Zandrini C, Pistarini C, Arrigo A, Franch F: La diidroergotossina mesilato dell'insufficienza cerebrovasculare cronica: analisi spettrale dell'EEG e correlati neuropsicologici. Farmaco 1983; 38:97-102 [A]
132. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helm MJ, Anthony JC: Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44:227-232 [D]
133. McGeer PL, Rogers J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992; 42:447-448 [G]
134. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F: Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43:1609-1611 [A]
135. Stewart WF, Kawas C, Corrada M, Metter EJ: Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48: 626-632 [C]
136. Aisen PS, Davis KL: Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151: 1105-1113 [G]
137. Sherwin BB: Estrogenic effects on memory in women. Ann NY Acad Sci 1994; 743:213-230 [G]
138. Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, Zabriskie J: Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986; 11:337-345 [B]
139. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N: Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995; 6(2):99-107 [G]
140. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG: Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994; 51:896-900 [D]
141. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348:429-432 [C]
142. Burns A, Murphy D: Protection against Alzheimer's disease? Lancet 1996; 348:420-421 [G]
143. Crapper-McLachlan DR, Dalton AJ, Kruck TPA, Bell MY, Smith WL, Kalow W, Andrews DF: Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991; 337: 1304-1308; correction 337:1618 [B]
144. Cardelli MB, Russell M, Bagne CA, Pomara N: Chelation therapy: unproved modality in the treatment of Alzheimer-type dementia. J Am Geriatr Soc 1985; 33:548-551 [G]
145. Leibovici A, Tariot PN: Agitation associated with dementia: a systematic approach to treatment. Psychopharmacol Bull 1988; 24:49-53 [G]
146. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48(May suppl): 9-15 [G]
147. Devanand DP, Sackeim HA, Brown RP, Mayeux R: Psychosis, behavioral disturbance, and the use of neuroleptics in dementia. Compr Psychiatry 1988; 29:387-401 [F]
148. Schneider LS, Pollack VE, Lyness SA: A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563 [E]
149. Rada RT, Kellner R: Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976; 24:105-107 [A]
150. Barnes R, Veith R, Okimoto J, Raskind M, Gumbrecht G: Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982; 139:1170-1174 [A]
151. Sugarman AA, Williams BH, Adierstein AM: Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964; 120: 1190-1192 [A]
152. Petrie WM, Ban TA, Berney S, Fujimori M, Guy W, Ragheb M, Wilson WH, Schaffer JD: Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982; 2:122-126 [A]
153. Hamilton LD, Bennett JL: The use ot trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962; 10:140-147 [A]
154. Hamilton LD, Bennett JL: Acetophenazine for hyperactive geriatric patients. Geriatrics 1962; 17:596-601 [A]
155. Abse DW, Dahlstrom WG, Hill C: The value of chemotherapy in senile mental disturbance. JAMA 1960; 174:2036-2042 [A]
156. Madhusoodanan S, Brenner R, Araujo L, Abaza A: Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995; 56:514-518 [G]
157. Friedman JH, Lannon MC: Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39:1219-1221 [G]
158. Chacko R, Hurley R, Jankovic J: Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 1993; 5:206-208 [G]
159. Salzman C, Vaccaro B, Lieff J, Weiner A: Clozapine in older patients with psychosis and behavioral disturbances. Am J Geriatr Psychiatry 1995; 3:26-33 [G]
160. Devanand DP, Sackeim HA, Brown RP, Mayeux R: A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46:854-857 [B]
161. Woerner MG, Alvir JMJ, Kane JM, Saltz BL, Lieberman JA: Neuroleptic treatment of elderly patients. Psychopharmacol Bull 1995; 31:333-337 [B]
162. Jeste DV, Caliguiri MP, Paulsen JS, Heaton RK, Lacro JP, Harris M, Bailey A, Fell RL, McAdams LA: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756-765 [B]
163. Salzman C: Treatment of the elderly agitated patient. J Clin Psychiatry 1987; 48(May suppl):19-22 [G]
164. Allen RL, Walker Z, D'Ath PJ, Katona CLE: Risperidone for psychotic and behavioural symptoms in Lewy body dementia (letter). Lancet 1995; 346:185 [G]
165. McKeith IG, Ballard CG, Harrison RW: Neuroleptic sensitivity to risperidone in Lewy body dementia (letter). Lancet 1995; 346:699 [G]
166. Gottlieb G, McAllister T, Gur R: Depot neuroleptics in the treatment of behavioral disorders in patients with Alzheimer's disease. J Am Geriatr Soc 1988; 36:619-621 [G]
167. Kirven LE, Montero EF: Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study. J Am Geriatr Soc 1973; 21:546-551 [A]
168. Covington J: Alleviating agitation, apprehension and related symptoms in geriatric patients. South Med J 1975; 68:719-724 [G]
169. Stotsky B: Multicenter study comparing thioridazine with diazepam and placebo in elderly nonpsychotic patients with emotional and behavioral disorders. Clin Ther 1984; 6:546-559 [A]
170. Coccaro EF, Kramer E, Zemishlany Z, Thorne A, Rice CM III, Giordani B, Duvvi K, Patel BM, Torres J, Nora R, Neufeld R, Mohs RC, Davis KL: Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147:1640-1645 [G]
171. Cevera AA: Psychoactive drug therapy in the senile patient: controlled comparison of thioridazine and diazepam. Psychiatry Digest 1974: pp 15-21 [A]
172. Beber CR: Management of behavior in the institutionalized aged. Dis Nerv Syst 1965; 26:591-595 [A]
173. Lemos GP, Clement MA, Nickels E: Effects of diazepam suspension in geriatric patients hospitalized for psychiatric illnesses. J Am Geriatr Soc 1965; 13:355-359 [A]
174. Salzman C: Clinical Geriatric Psychopharmacology, 2nd ed. Baltimore, Williams & Wilkins, 1992 [G]
175. Grad R: Benzodiazepines for insomnia in community-dwelling elderly: a review of benefit and risk. J Fam Pract 1995; 41:473-481 [F]
176. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F: Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995; 155:1801-1807 [D]
177. Ashton H: Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994; 48:25-40 [G]
178. Gleason RP, Schneider LS: Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51:115-118 [G]
179. Lemke MR: Effect of carbamazepme on agitation in Alzheimer's inpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56:354-357 [B]
180. Tariot PN, Erb R, Leibovici A, Podgorski CA, Cox C, Asnis J, Kolassa J, Irvine C: Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42:1160-1166 [B]
181. Chambers CA, Bain J, Rosbottom R, Ballinger BR, McLaren S: Carbamazepine in senile dementia and overactivity: a placebo controlled double blind trial. IRCS Med Sci 1982; 10:505-506 [A]
182. Lott AD, McElroy SL, Keys MA: Valproate in the treatment of behavioral agitation in elderly patients with dementia. J Neuropsvchiatry Clin Neurosci 1995; 7:314-319 [G]
183. Mellow AM, Solano-Lopez C, Davis S: Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol 1993; 6:205-209 [G]
184. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 1994; 151 (Dec suppl)[G]
185. Risse SC, Barnes R: Pharmacologic treatment of agitation associated with dementia. J Am Geriatr Soc 1986; 34:368-376 [A]
186. Kunik ME, Yudofsky SC, Silver JM, Hales RE: Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 1994; 55(Feb suppl):13-17 [G]
187. Simpson DM, Foster D: Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry 1986; 47: 191-193 [G]
188. Nair NP, Ban TA, Hontela S, Clarke R: Trazodone in the treatment of organic brain syndromes, with special reference to psychogeriatrics. Curr Ther Res 1973; 15:769-775 [G]
189. Houlihan DJ, Mulsant BH, Sweet RA, Rifai AH, Pasternak R, Rosen J, Zubenko GS: A naturalistic study of trazodone in the treatment of behavioral complications of dementia. Am J Geriatr Psychiatry 1994; 2:78-85 [G]
190. Lebert F, Pasquier F, Petit H: Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry 1994; 55:536-538 [B]
191. Sultzer D, Gray KF, Gunay I, Berisford MA, Mahler ME: A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5:60-69 [A]
192. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990; 157:894-901 [R]
193. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum HE, Ofsti E, Eriksson S, Syversen S: A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992; 86:138-145 [B]
194. Colenda CC III: Buspirone in treatment of agitated demented patient (letter). Lancet 1988; 1:1169; correction 1988; 2:754 [G]
195. Tiller JW, Dakis JA, Shaw JM: Short-term buspirone treatment in disinhibition with dementia (letter). Lancet 1988; 2:510 [G]
196. Sakauye KM, Camp CJ, Ford PA: Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993; 1:82-84 [B]
197. Weiner MF, Denke M, Williams K, Guzman R: Intramuscular medroxyprogesterone acetate for sexual aggression in elderly men. Lancet 1992; 339:1121-1122 [G]
198. Kyomen H, Nobel K, Wet J: The use of estrogen to decrease aggressive physical behavior in elderly men with dementia. J Am Geriatr Soc 1991; 39:1110-1112 [G]
199. Rich SS, Ovsiew F: Leuprolide acetate for exhibitionism in Huntington's disease. Mov Disord 1994; 9:353-357 [G]
200. Weiler PG, Mungas D, Bernick C: Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988; 1:226-230 [G]
201. Reifler BV, Teri L, Raskind M, Veith R, Barnes R, White E, McLean P: Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989; 146:45-49 [A]
202. Passeri M, Cucinotta D, DeMello M, Biziere K: Comparison of minaprine and placebo in the treatment of Alzheimer's disease and multi-infarct dementia. Int J Geriatr Psychiatry 1987; 2:97-103 [B]
203. Fuchs A, Henke U, Erhart DH, Schell CH, Pramshohler B, Danninger B, Schautzer F: Video rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry 1993; 26:37-41 [B]
204. Conti L, Fosca RE, Lazzerini F, Morey LC, Ban TA, Santini V, Modafferi A, Postiglione A: Glycosaminoglycan polysulfate (Ateroid) in old-age dementias: effects upon depressive symptomatology in geriatric patients. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:977-981 [B]
205. Passeri M, Cucinotta D, Abate G, Senin LI, Ventura A, Badiale MS, Diana R, La Greca P, Le Grazie C: Oral 5′-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging 1993; 5:63-71 [B]
206. NIH Consensus Development Panel on Depression in Late Life: Diagnosis and treatment of depression in late life. JAMA 1992; 268:1018-1024 [G]
207. American Psychiatric Association: Practice Guideline for Major Depressive Disorder in Adults. Am J Psychiatry 1993; 150 (April suppl)[G]
208. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B: Apathy: a treatable syndrome. Clin Neuroscience 1995; 7(1):23-30 [G]
209. Wallace AE, Kofoed LL, West AN: Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152:929-931 [A]
210. Pickett P, Masand P, Murray G: Psychostimulant treatment of geriatric depressive disorders secondary to medical illness. J Geriatr Psychiatry Neurol 1990; 3:146-151 [G]
211. Lazarus LW, Moberg PJ, Langsley PR, Lingam VR: Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch Phys Med Rehabil 1994; 75:403-406 [G]
212. Price TR, McAllister TW: Safety and efficacy of ECT in depressed patients with dementia: a review of clinical experience. Convulsive Ther 1989; 5:1-74 [G]
213. Aharon-Peretz J, Masiah A, Pillar T, Epstein R, Tzischinsky O, Lavie P: Sleep-wake cycles in multi-infarct dementia and dementia of the Alzheimer type. Neurology 1991; 41:1616-1619 [G]
214. Satlin A: Sleep disorders in dementia. Psychiatr Ann 1994; 24: 186-190 [G]
215. Hoch CC, Reynolds CF III, Houck PR: Sleep patterns in Alzheimer, depressed, and healthy elderly. West J Nurs Res 1988; 10: 239-256 [G]
216. Strollo P, Rogers R: Obstructive sleep apnea. N Engl J Med 1996; 334:99-104 [G]
217. Piccione P, Zorick F, Lutz T, Grissom T, Kramer M, Roth T: The efficacy of triazolam and chloral hydrate in geriatric insomniacs. J Int Med Res 1980; 8:361-367 [B]
218. Linnoila M, Viukari M, Numminen A, Auvinen J: Efficacy and side effects of chloral hydrate and tryptophan as sleeping aids in psychogeriatric patients. Int Pharmacopsychiatry 1980; 15: 124-128 [B]
219. Shaw SH, Curson H, Coquelin JP: A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992; 20:150-161; correction 20:494 [A]
220. Satlin A, Volicer L, Ross V, Herz L, Campbell S: Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry 1992; 149:1028-1032 [B]
221. Okawa M, Mishima K, Nanami T, Shimizu T, Iijima S, Hishikawa Y, Takahashi K: Vitamin B12 treatment for sleep-wake rhythm disorders. Sleep 1990; 13(1):15-23 [A]
222. Mishima K, Okawa M, Hishikawa Y, Hozumi S, Hon H, Takahashi K: Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatr Scand 1994; 89:1-7 [B]
223. Maurizi CP: The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer's disease and abnormal aging. Med Hypotheses 1990; 31:233-242 [E]
224. Singer C, McArthur A, Hughes R, Sack R, Kaye J, Lewy A: High dose melatonin administration and sleep in the elderly. Sleep Res 1995;24A:151 [G]
225. Volicer L, Volicer BJ, Hurley AC: Is hospice care appropriate for Alzheimer patients? Caring 1993; 12(11):50-55 [G]
226. Volicer L, Hurley AC, Lathi DC, Kowall NW: Measurement of severity in advanced Alzheimer's disease. J Gerontol 1994; 49(5):M223-M226 [G]
227. Levkoff SE, Evans DA, Liptzin B, Wetle T, Reilly C, Pilgrim D, Schor J, Rowe J: Delirium: the occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med 1992; 152:334-340 [G]
228. Erkinjuntti T, Wikstrom J, Palo J, Autio L: Dementia among medical inpatients. Arch Intern Med 1986; 146:1923-1926 [C]
229. Tune L, Carr S, Hoag E, Cooper T: Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149:1393-1394 [G]
230. 123I-IMP SPECT in patients with cerebral arteriosclerosis. Clin Ther 1994; 16:65-73 [G]
231. Blume J, Ruhlmann KU, de la Haye R, Rettig K: Treatment of chronic cerebrovascular disease in elderly patients with pentoxifylline. J Med 1992; 23:417-432 [A]
232. Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP: Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 1992; 40:237-244 [A]
233. Rovner BW, Kafonek S, Filipp L, Lucas MJ, Folstein MF: Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986; 143:1446-1449 [G]
234. Boss P, Caron W, Horbal J, Mortimer J: Predictors of depression in caregivers of dementia patients: boundary ambiguity and mastery. Fam Process 1990; 29:245-254 [G]
235. Dura JR, Stukenberg KW, Kiecolt-Glaser JK: Chronic stress and depressive disorders in older adults. J Abnorm Psychol 1990; 99:284-290 [D]
236. Tariot PN, Podgorski CA, Blazina L, Leibovici A: Mental disorders in the nursing home: another perspective. Am J Psychiatry 1993; 150:1063-1069 [G]
237. Sloane PD, Barrick AL: Improving long-term care for persons with Alzheimer's disease (editorial). J Am Geriatr Soc 1996; 44:91-92 [G]
238. Lawton MP, Brody EM, Saperstein AR: A controlled study of respite service for caregivers of Alzheimer's patients. Gerontologist 1989; 29:8-16 [B]
239. Pynoos J, Regnier V: Improving residential environments for frail elderly: bridging the gap between theory and application, in The Concept and Measurement of Quality of Life in the Frail Elderly. Edited by Birren JE, Lubben JE, Rowe JC, Deutchman DE. San Diego, Academic Press, 1991, pp 91-119 [G]
240. Horwitz GJ, Tariot PN, Mead K, Cox C: Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry 1995; 3:290-299 [C]
241. Tinetti ME, Liu WL, Marottoli RA, Ginter SF: Mechanical restraint use among residents of skilled nursing facilities. JAMA 1991; 265:468-471 [G]
242. Burton LC, German PS, Rovner BW, Brant LJ: Physical restraint use and cognitive decline among nursing home residents. J Am Geriatr Soc 1992; 40:811-816 [C]
243. Capezuti E, Evans L, Strumpf N, Maislin G: Physical restraint use and falls in nursing home residents. J Am Geriatr Soc 1996; 44:627-633 [D]